Severe cutaneous adverse reaction associated with vemurafenib: <scp>DRESS</scp>,<scp> AGEP</scp> or overlap reaction?
A. Gey(Hôpital Saint-André), Thomas Jouary(Hôpital Saint-André), Alain Taı̈eb(Hôpital Saint-André), B. Milpied(Hôpital Saint-André), G. Perro(Hôpital Pellegrin), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Khaled Ezzedine(Hôpital Saint-André), Caroline Robert(Centre National de la Recherche Scientifique), Christine Mateus(Centre National de la Recherche Scientifique)
Cited by 30
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k